Ana Svensson
Dr. Ana Svensson is the Vice President of Clinical, Medical, and Regulatory Affairs at Novo Nordisk Oceania. She has been instrumental in advocating for broader access to GLP-1 therapies for obesity in Australia, emphasizing the need for affordability and equity in treatment options. Svensson has played a key role in the company's efforts to secure a listing for Wegovy on the Pharmaceutical Benefits Scheme (PBS) to improve access to obesity treatments for Australians.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Australia | 1 | 7.00 | 0.09% | +0% | 25,499,884 | 22,808 | $1,380,000 | 1,234$ |
| Totals | 1 | 25,499,884 | 22,808 | $1,380,000 | 1,234$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Australia:
Dr Ana Svensson, vice president at Novo Nordisk Oceania, stated the company is working to secure a PBS listing for Wegovy.
7